Drug intelligence / Profile preview

TH07

Development stage: Phase 3
Lead developer: Triple Hair
Modality: Small Molecules
Administration: Topical

Overview

**TH07** is an investigational, patented fixed-dose topical solution developed by Triple Hair for **male androgenic alopecia**. It combines **finasteride**, **latanoprost**, and **minoxidil** in a once-daily topical product intended to address complementary hair-follicle pathways: reduction of dihydrotestosterone formation, prostaglandin F receptor signaling, and potassium-channel-associated stimulation of hair growth. TH07 is being evaluated in Phase III studies in men with androgenic alopecia. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435012))

Other names: Therapy-07Therapy07Therapy 07

Targets

PTGFR (Prostaglandin F2 alpha receptor)KATP channel (ATP-sensitive potassium channel)SRD5A2 (Steroid 5-alpha-reductase type II)

Beyond the preview

Go deeper on TH07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TH07.

Explore the full profile